The document discusses the use of aspirin for the primary prevention of cardiovascular disease in patients with diabetes. While aspirin is proven to be effective for secondary prevention, its benefits for primary prevention in patients without a history of vascular disease are unclear based on previous studies which have been underpowered. The document describes two recent clinical trials, POPADAD and JPAD, which also did not provide definitive evidence due to low event rates. It encourages participation in the ongoing ASCEND trial, which aims to recruit 10,000 patients, in order to help resolve the uncertainty around aspirin's role in primary prevention for patients with diabetes.